NAME: Sophie ALAIN-ALBERTINI20th september 1962, Paris, FranceMarried, 4 childrenFUNCTION Professor of virology, MD PhD Coordinator of the French

Cytomegaloviruses Natonal Reference Center

Director of the genomics (NGS) platorm GenoLim, of Limoges university hospital

Co-director of the Inserm Unit U1092 RESINFIT, University of Limoges

Responsible for the viral genotyping and phenotyping/recombinant viruses platorm C-Lim, University of Limoges

PROFESSIONNAL ADDRESS

Laboratory of Bacteriology - Virology - HygienCenter for Biology and Research in Healthcare (CBRS)University Hospital Limoges2, avenue Martn Luther-King, F-87042 Limoges, France

INSERM Team RESINFIT (UMR1092)GEIST Research InsttuteFaculty of Medicine, University of Limoges, FR2, rue du Dr Marcland, F-87025 Limoges, France

Phone :(33) 5 55 05 67 24E-maill : sophie.alain@unilim.fr ORCID ID: htp://orcid.org/0000-0002-9787-1421 (sophie.alain@unilim.fr)

MEMBER OF SCIENTIFIC SOCIETY OR NETWORK

French Society of Microbiology, since 1993ECCMID since 2017I-REIVAC (F-CRIN): innovatve clinical research network in vaccinology since 2007FHU SUPORT: Solid OrganTransplantaton Network, since 2014QCMD: European molecular diagnosis quality control, for CMV drug resistance and viral load, since 2012

MAJOR ACTIVITIES AND RESEARCH TOPICS

Sophie ALAIN is a medical doctor and a virologist that exert her actvity both in the virology laboratory and in the research team. Her major actvity is devoted to Cytomegalovirus (CMV). Working since several years on CMV epidemiology and resistance to antvirals, in its various

pathological context (AIDS, congenital infecton, transplant patents), her research actvity focuses on antviral targets and escape mechanisms. These fundamental actvites join clinical research actvity through the French Herpesviruses Reference Center coordinaton. With two major studies ongoing : i) Survey of CMV resistance to antvirals in the solid organ and stem cell transplant setng and ii) Epidemiology of CMV infecton in France, in both congenital infecton and young children, in a vaccine perspectve. She is French primary investgator for Solstce assay (Shire/Takeda) on maribavir as rescue therapy, and coordinator of the Navire French Cohort (new and current ant-CMV drugs survey in stem cell recipients) that will begin in September 2019. Her clinical research actvity also covers molecular and clinical epidemiology of various viruses, with some impact on vaccine perspectves, such as varicella-zoster virus or hepatts B virus. Sophie Alain is also a member of the REIVAC French vaccinology network.

CLINICAL RESEARCH (as Primary investgator) in the feld of ant-CMV moleculesNAVIRE Cohort : French survey for efcacy of new ant CMV in allogenic stem cell transplant recipients (Industrial and academic partnership) beginning april 2020. Internatonal protocol Solstce SHP303, Shire/Takeda (Primary Investgator France) recruitngMerck IIS 2017 on letermovir efciency and toxicity in Placenta, completed.

ORPHAVIC Cohort for resistance survey and risk factor (450 patents )(Health Ministry Grant) a n d Quantc R+ (72 Kidney transplant recipeints R+)observatonal Quantferon study NCT: NCT02067169 et NCT02064699, recruitment completed, analysis ongoing.

Recent publicatons 2018-2020

ALSULIMAN T, KITEL C, DULERY R, GUILLAUME T, LAROSA F, CORNILLON J, LABUSSIÈRE-WALLET H, MÉDIAVILLA C, BELAICHE S, DELAGE J, ALAIN S, YAKOUB-AGHA I. Cytotect®CP as salvage therapy in patents with CMV infecton following allogeneic hematopoietc cell transplantaton: a multcenter retrospectve study. Bone Marrow Transplant. 2018 Oct;53(10):1328-1335.

KOTTON CN, KUMAR D, CALIENDO AM, HUPRIKAR S, CHOU S, DANZIGER-ISAKOV L, HUMAR A. The Transplantaton Society Internatonal CMV Consensus Group. The Third Internatonal Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantaton. Transplantaton. 2018 Jun;102(6):900-931.

NOBLE J, GATAULT P, SAUTENET B, GAUDY-GRAFFIN C, BEBY-DEFAUX A, THIERRY A,ESSIG M, HALIMI JM, MUNTEANU E, ALAIN S, BUCHLER M. Predictve factors of spontaneous CMV DNAemia clearance in kidney transplantaton. J Clin Virol. 2018 Feb - Mar;99-100:38-43.

PIRET J, SCHIBLER M, PHAM VD, HANTZ S, GIANNOTTI F, MASOURIDI-LEVRAT S, KAISER L, GOYETTE N, ALAIN S, SHI R, BOIVIN G. Compartmentalizaton of a Multdrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalits. J Infect Dis. 2019 Jun 13. [Epub ahead of print]

ROBIN C, THIEBAUT A, ALAIN S, DE FONTBRUNE FS, BERCEANU A, D'AVENI M, CEBALLOS P, REDJOUL R, NGUYEN-QUOC S, BÉNARD N, PAHLAVAN-GRUMEL G, CORDONNIER C. Letermovir for secondary prophylaxis of CMV infecton and disease afer allogeneic hematopoietc cell transplantaton: Results from the French compassionate program. Biol Blood Marrow Transplant. 2020 Feb 5. pii:S1083-8791(20)30060-4. doi: 10.1016/j.bbmt.2020.01.027. [Epub ahead of print] PubMed PMID: 32035273.